Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Reuters NewMedia - August 6, 2009
Second-line antiretroviral therapies and a drug used to treat tuberculosis for those with drug-resistant HIV/AIDS will be made available at a reduced cost and in more convenient regimens, saving as many as hundreds of thousands of lives in the developing world, Clinton said.
"Today's announcement will help ensure we can sustain treatment over a lifetime and better treat patients with both HIV and TB, two key steps in turning the tide of the global HIV/AIDS pandemic," Clinton told reporters at his foundation's headquarters in Manhattan.
Starting in 2010, Matrix, a unit of U.S.-based Mylan Inc <MYL.O>, will make four drugs available at a cost of $425 per year. The discount will result in $400 million in savings over the next five years compared to prices commonly paid for alternative regimens, the foundation said.
In addition, Matrix said it would create a more convenient regimen for taking the drugs, allowing patients to take pills just once per day.
Pfizer will offer the tuberculosis drug rifabutin in 10 countries for $1 per dose, or $90 for a full course of treatment over six months.
Tuberculosis is the leading cause of death among those with HIV/AIDS, Clinton said. (Reporting by Edith Honan, Editing by Michelle Nichols and Eric Beech)
090806
RE090804
Copyright © 2009 - Reuters, Ltd. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Contact Reuters.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .